Powered by
ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …
ANN ARBOR—Esperion Therapeutics Inc. has named veteran cardiovascular pharmaceutical industry executive Sheldon Koenig as its chief operating officer. Koenig will report to president and CEO Tim M. Mayleben. In this …
ANN ARBOR—Esperion Therapeutics Inc. reported a loss of $85.4 million or $3.07 a share in the third quarter of 2020, vs. a loss of $68.4 million or $2.52 a share …
LANSING—The board of the Michigan Strategic Fund has approved state aid for two business expansions and a community project that will generate a total of $154.7 million in capital investment …
ANN ARBOR–Officials at Esperion Therapeutics Inc. (Nasdaq: ESPR) announced record revenue in the second quarter ended June 30, as its cholesterol-fighting drugs Nexletol and Nexlizet have been approved for use …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup developing new drugs for endocrine diseases, announced that it had engaged SVB Leerink, a Boston-based investment bank, in a “strategic review …
CANTON TWP.—The life sciences regulatory and clinical data consultant MMS Holdings announced it had been retained by Thunder Bay, Ontario-based IGY Life Sciences to further the development of IgY-110, an …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …
ANN ARBOR—BlueWillow Biologics, a firm founded in 1999 that is developing nanotechnology for healthcare applications, announced the availability of NanoBio Protect on Amazon. NanoBio Protect is an alcohol-free antiseptic solution that …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company developing novel treatments for endocrine diseases with significant unmet needs, reported a loss of $12 million or 65 cents per …